vs

Side-by-side financial comparison of GCI Liberty, Inc. (GLIBA) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

GCI Liberty, Inc. is the larger business by last-quarter revenue ($257.0M vs $225.6M, roughly 1.1× Organogenesis Holdings Inc.). Organogenesis Holdings Inc. runs the higher net margin — 19.4% vs -150.6%, a 170.0% gap on every dollar of revenue. Organogenesis Holdings Inc. produced more free cash flow last quarter ($34.8M vs $21.0M).

GCI Communication Corp (GCI) is a telecommunications corporation operating in Alaska. Through its own facilities and agreements with other providers, GCI provides Internet access, landline, and cellular telephone service. It is a subsidiary of GCI Liberty, Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

GLIBA vs ORGO — Head-to-Head

Bigger by revenue
GLIBA
GLIBA
1.1× larger
GLIBA
$257.0M
$225.6M
ORGO
Higher net margin
ORGO
ORGO
170.0% more per $
ORGO
19.4%
-150.6%
GLIBA
More free cash flow
ORGO
ORGO
$13.8M more FCF
ORGO
$34.8M
$21.0M
GLIBA

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GLIBA
GLIBA
ORGO
ORGO
Revenue
$257.0M
$225.6M
Net Profit
$-387.0M
$43.7M
Gross Margin
Operating Margin
-189.9%
28.1%
Net Margin
-150.6%
19.4%
Revenue YoY
78.1%
Net Profit YoY
469.5%
EPS (diluted)
$-13.34
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GLIBA
GLIBA
ORGO
ORGO
Q4 25
$225.6M
Q3 25
$257.0M
$150.9M
Q2 25
$261.0M
$101.0M
Q1 25
$86.7M
Q4 24
$126.7M
Q3 24
$115.2M
Q2 24
$130.2M
Q1 24
$110.0M
Net Profit
GLIBA
GLIBA
ORGO
ORGO
Q4 25
$43.7M
Q3 25
$-387.0M
$21.6M
Q2 25
$27.0M
$-9.4M
Q1 25
$-18.8M
Q4 24
$7.7M
Q3 24
$12.3M
Q2 24
$-17.0M
Q1 24
$-2.1M
Gross Margin
GLIBA
GLIBA
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Q1 24
73.9%
Operating Margin
GLIBA
GLIBA
ORGO
ORGO
Q4 25
28.1%
Q3 25
-189.9%
13.7%
Q2 25
19.5%
-12.5%
Q1 25
-30.9%
Q4 24
8.1%
Q3 24
5.4%
Q2 24
-10.7%
Q1 24
-3.5%
Net Margin
GLIBA
GLIBA
ORGO
ORGO
Q4 25
19.4%
Q3 25
-150.6%
14.3%
Q2 25
10.3%
-9.3%
Q1 25
-21.7%
Q4 24
6.1%
Q3 24
10.7%
Q2 24
-13.1%
Q1 24
-1.9%
EPS (diluted)
GLIBA
GLIBA
ORGO
ORGO
Q4 25
$0.31
Q3 25
$-13.34
$0.11
Q2 25
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$0.09
Q2 24
$-0.13
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GLIBA
GLIBA
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$124.0M
$93.7M
Total DebtLower is stronger
$985.0M
Stockholders' EquityBook value
$1.4B
$300.1M
Total Assets
$3.0B
$598.7M
Debt / EquityLower = less leverage
0.72×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GLIBA
GLIBA
ORGO
ORGO
Q4 25
$93.7M
Q3 25
$124.0M
$63.7M
Q2 25
$104.0M
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Q1 24
$88.6M
Total Debt
GLIBA
GLIBA
ORGO
ORGO
Q4 25
Q3 25
$985.0M
Q2 25
$987.0M
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
GLIBA
GLIBA
ORGO
ORGO
Q4 25
$300.1M
Q3 25
$1.4B
$255.1M
Q2 25
$233.2M
Q1 25
$242.9M
Q4 24
$262.9M
Q3 24
$278.5M
Q2 24
$263.5M
Q1 24
$278.0M
Total Assets
GLIBA
GLIBA
ORGO
ORGO
Q4 25
$598.7M
Q3 25
$3.0B
$509.8M
Q2 25
$3.4B
$461.1M
Q1 25
$467.4M
Q4 24
$497.9M
Q3 24
$446.3M
Q2 24
$443.2M
Q1 24
$458.5M
Debt / Equity
GLIBA
GLIBA
ORGO
ORGO
Q4 25
Q3 25
0.72×
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GLIBA
GLIBA
ORGO
ORGO
Operating Cash FlowLast quarter
$76.0M
$39.4M
Free Cash FlowOCF − Capex
$21.0M
$34.8M
FCF MarginFCF / Revenue
8.2%
15.4%
Capex IntensityCapex / Revenue
21.4%
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GLIBA
GLIBA
ORGO
ORGO
Q4 25
$39.4M
Q3 25
$76.0M
$3.1M
Q2 25
$226.0M
$-32.9M
Q1 25
$-19.9M
Q4 24
$10.9M
Q3 24
$8.7M
Q2 24
$4.7M
Q1 24
$-10.2M
Free Cash Flow
GLIBA
GLIBA
ORGO
ORGO
Q4 25
$34.8M
Q3 25
$21.0M
$844.0K
Q2 25
$107.0M
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
Q1 24
$-12.4M
FCF Margin
GLIBA
GLIBA
ORGO
ORGO
Q4 25
15.4%
Q3 25
8.2%
0.6%
Q2 25
41.0%
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Q1 24
-11.3%
Capex Intensity
GLIBA
GLIBA
ORGO
ORGO
Q4 25
2.1%
Q3 25
21.4%
1.5%
Q2 25
45.6%
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Q1 24
2.0%
Cash Conversion
GLIBA
GLIBA
ORGO
ORGO
Q4 25
0.90×
Q3 25
0.14×
Q2 25
8.37×
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons